Neoadjuvant Intravesical Therapy for Non–muscle-invasive Bladder Cancer: A New Approach for Old Agents?
Author:
- 1 December 2020
- journal article
- editorial
- Published by Elsevier in European Urology
- Vol. 78 (6) , 863-864
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non–muscle-invasive Bladder Cancer—A Randomised Controlled TrialEuropean Urology, 2020
- Chemoablation in Urothelial Carcinoma: A Systematic Review and Future PerspectivesUrology, 2020
- Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) membersUrologic Oncology: Seminars and Original Investigations, 2020
- CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancerBJU International, 2020
- Low adherence to guidelines in non-muscle-invasive diseaseNature Reviews Urology, 2016
- Active surveillance for low‐risk non‐muscle‐invasive bladder cancer: mid‐term results from the Bladder cancer Italian Active Surveillance ( BIAS ) projectBJU International, 2016
- Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non–muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 StudyEuropean Urology, 2012
- Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicinBritish Journal of Urology, 1994